A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). (4th November 2015) - Long, Georgina V; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert HI; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony J; Gajewski, Thomas F; et al.